Abstract: Objective To evaluate the efficacy and safety in treatment of macular edema (ME) secondary to central retinal vein occlusion(CRVO) by intravitreal bevacizumab (IVB) with intravitreal triamcinolone acetonide (IVT) for first priority. Design Meta-analysis. Participants Published literature in Medline, EMbase, Cochrane library and CBM which comparing IVB with IVT in treatment of ME secondary to CRVO for first priority. Method According to evaluation guidelines of Cochrane collaboration, clinical controlled trials (CCTs) were searched using Medline, EMbase, the Cochrane Library and CBM. Methodology qualities of literatures were performed by experienced researchers according to the Jadad Score. RevMan 5.1 offered by Cochrane was used to do the meta-analysis. Main Outcome Measures Central macular thickness(CMT), best corrected visual acuity(BCVA), and adverse events. Results Only 6 literatures came into meta-analysis (242 eyes). No significant difference in either CMT(P=0.12) or BCVA (P=0.92) was observed between IVB and IVT group. Adverse event rates (mainly elevation of intraocular pressure and progression of cataracts) in IVT group was 33 times （95%CI: 10 times~100 times） more than IVB group(P<0.001).  Conclusion Meta-analysis shows that the equal reduced CMT and BCVA  was observed in IVT group and in IVB group for treatment of ME secondary to CRVO, while the adverse event rate in IVT group is much more than in IVB group. More high quality perspective studies are still required for further analysis.

Key words: bevacizumab, triamcinolone, central retinal vein occlusion, macular edema, meta-analysis